Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials - 01/02/21
Doi : 10.1016/j.jaci.2020.12.228
Mark Liu, MD FAAAAI 1, Camille Taillé 2, Jason Lee, MD FAAAAI 3, Steven Smith, PhD MSc 4, Steve Mallett, MSc 5, Neil Martin, MD 6, Peter Howarth, MD 6, Steven Yancey, MS MBA 4, Catherine Lemiere, MD MSc 7
1 Pulmonary and Critical Care Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA
2 Hôpital Bichat, AP-HP-Nord, Université de Paris, F-CRIN CRISALIS, Paris, France
3 Toronto Allergy and Asthma Clinic, Toronto, ON, Canada
4 GSK, Research Triangle Park, NC, USA
5 GSK, Stockley Park, Uxbridge, Middlesex, UK
6 GSK, Brentford, Middlesex, UK
7 Université de Montréal, Montreal, QC Canada, Hôpital du Sacré-Cœur de Montréal, Montreal, QC Canada
174
Il testo completo di questo articolo è disponibile in PDF.Mappa
© 2020
Pubblicato da Elsevier Masson SAS.
Vol 147 - N° 2S
P. AB56 - Febbraio 2021 Ritorno al numero
Articolo precedente
- Managing Patients with Severe Asthma and Common Comorbidities of Atopy, Obesity & Depression/Anxiety: Real-world Effectiveness of Mepolizumab
- Nestor Molfino, Thomas Casale, Jared Silver, Michael Bogart, Elizabeth Packnett, Donna McMorrow, Juan Wu, Beth Hahn
- Treatment with Tezepelumab Reduces Serum Interleukin (IL)-5 and IL-13 in Patients with Severe, Uncontrolled Asthma to Levels Approaching those Observed in Healthy Individuals
- Tuyet-Hang Pham, Janet Griffiths, Gene Colice, Jane Parnes, Claudia Chen, Bill Cook
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?